CO7030960A2 - Inhibidores de pak para el tratamiento de los trastornos de proliferación celular - Google Patents

Inhibidores de pak para el tratamiento de los trastornos de proliferación celular

Info

Publication number
CO7030960A2
CO7030960A2 CO14119704A CO14119704A CO7030960A2 CO 7030960 A2 CO7030960 A2 CO 7030960A2 CO 14119704 A CO14119704 A CO 14119704A CO 14119704 A CO14119704 A CO 14119704A CO 7030960 A2 CO7030960 A2 CO 7030960A2
Authority
CO
Colombia
Prior art keywords
treatment
cell proliferation
proliferation disorders
pak inhibitors
pak
Prior art date
Application number
CO14119704A
Other languages
English (en)
Inventor
Sergio Duron
David Campbell
Original Assignee
Afraxis Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afraxis Holdings Inc filed Critical Afraxis Holdings Inc
Publication of CO7030960A2 publication Critical patent/CO7030960A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CO14119704A 2011-11-04 2014-06-04 Inhibidores de pak para el tratamiento de los trastornos de proliferación celular CO7030960A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161555902P 2011-11-04 2011-11-04

Publications (1)

Publication Number Publication Date
CO7030960A2 true CO7030960A2 (es) 2014-08-21

Family

ID=48192852

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14119704A CO7030960A2 (es) 2011-11-04 2014-06-04 Inhibidores de pak para el tratamiento de los trastornos de proliferación celular

Country Status (20)

Country Link
US (2) US20150031693A1 (es)
EP (2) EP2773643A4 (es)
JP (2) JP2015501786A (es)
KR (2) KR20140096098A (es)
CN (2) CN104039786A (es)
AR (1) AR089175A1 (es)
AU (2) AU2012327187A1 (es)
BR (2) BR112014010631A2 (es)
CA (2) CA2854471A1 (es)
CL (2) CL2014001132A1 (es)
CO (1) CO7030960A2 (es)
CR (2) CR20140251A (es)
EA (2) EA201490927A1 (es)
IL (2) IL232154A0 (es)
MA (2) MA35661B1 (es)
MX (2) MX2014005292A (es)
PH (1) PH12014500995A1 (es)
SG (2) SG11201401914WA (es)
TW (1) TW201326169A (es)
WO (2) WO2013067423A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580216A4 (en) * 2010-06-10 2014-07-23 Afraxis Holdings Inc 8- (SULFONYLBENZYL) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
SG11201401937YA (en) 2011-11-04 2014-05-29 Hoffmann La Roche New aryl-quinoline derivatives
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
WO2015011252A1 (en) * 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Pyrimidine-pyridinone serine/threonine kinase inhibitors
EP3102577B1 (en) * 2014-02-07 2018-07-18 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor receptor inhibitors
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN108697386B (zh) * 2016-02-17 2022-03-04 纽洛斯公司 用于检测生理状态的***和方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017220516A1 (en) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2018013466A2 (en) * 2016-07-15 2018-01-18 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of endocrine resistance in breast cancer
CN106818805A (zh) * 2016-12-27 2017-06-13 东莞市联洲知识产权运营管理有限公司 一种天然乙酰胆碱酯酶抑制剂及其杀虫应用
CN107083428B (zh) * 2017-04-10 2020-09-25 徐州医科大学 Pak5在癌症诊断预后治疗及药物筛选中的应用
US20220002429A1 (en) * 2018-10-24 2022-01-06 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
JP2022517189A (ja) * 2019-01-03 2022-03-07 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
CN112213400B (zh) * 2019-07-09 2022-06-07 四川弘合生物科技有限公司 一种β-榄香烯及其有关物质的检测方法
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc GCN2 and PERK kinase inhibitors and methods of using them
WO2022152259A1 (zh) * 2021-01-15 2022-07-21 江苏先声药业有限公司 Cdk2/4/6抑制剂及其制备方法和应用
CN113046323A (zh) * 2021-04-02 2021-06-29 四川农业大学 一种基于miR-532-5p及其靶基因调控卵巢颗粒细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A3 (en) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
EP2112150B1 (en) * 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
US8674095B2 (en) * 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
US8372970B2 (en) * 2009-10-09 2013-02-12 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US8912203B2 (en) * 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2580216A4 (en) * 2010-06-10 2014-07-23 Afraxis Holdings Inc 8- (SULFONYLBENZYL) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Also Published As

Publication number Publication date
EP2773643A4 (en) 2015-07-29
CA2854471A1 (en) 2013-05-10
CN104039786A (zh) 2014-09-10
KR20140105451A (ko) 2014-09-01
MX2014005292A (es) 2014-09-11
CR20140251A (es) 2014-08-20
IL232215A0 (en) 2014-06-30
AU2012327183A8 (en) 2013-07-18
AU2012327187A1 (en) 2013-05-23
MA35661B1 (fr) 2014-11-01
WO2013067423A1 (en) 2013-05-10
EA201490925A1 (ru) 2014-09-30
EP2773642A1 (en) 2014-09-10
AR089175A1 (es) 2014-08-06
IL232154A0 (en) 2014-05-28
WO2013067434A1 (en) 2013-05-10
SG11201401914WA (en) 2014-05-29
KR20140096098A (ko) 2014-08-04
EP2773643A1 (en) 2014-09-10
JP2014532724A (ja) 2014-12-08
US20150031693A1 (en) 2015-01-29
BR112014010631A2 (pt) 2017-04-25
EA201490927A1 (ru) 2014-10-30
AU2012327187A8 (en) 2013-07-25
BR112014010420A2 (pt) 2017-04-25
PH12014500995A1 (en) 2014-08-04
AU2012327183A1 (en) 2013-05-30
TW201326169A (zh) 2013-07-01
US20130116263A1 (en) 2013-05-09
CR20140250A (es) 2014-08-20
JP2015501786A (ja) 2015-01-19
SG11201401996TA (en) 2014-05-29
MA35660B1 (fr) 2014-11-01
CL2014001131A1 (es) 2014-08-22
CA2854462A1 (en) 2013-05-10
CN104093717A (zh) 2014-10-08
CL2014001132A1 (es) 2014-08-22
MX2014005296A (es) 2014-08-27

Similar Documents

Publication Publication Date Title
CO7030960A2 (es) Inhibidores de pak para el tratamiento de los trastornos de proliferación celular
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
DOP2012000282A (es) Indoles sustituidos como inhibidores ezh2
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
BR112015004373A2 (pt) implante adequado para osteotomia do calcâneo
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CR20140177A (es) Métodos para el tratamiento de vhc
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112012030923A2 (pt) derivados de piperidinona como inibidores mdm2 para o tratamento de câncer
BR112013020220A2 (pt) métodos para determinação de ploidia pré-natal não invasiva
CO6940432A2 (es) Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
CO6821964A2 (es) Compuestos para el tratamiento de la adicción
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
UY34401A (es) Métodos para el tratamiento de hcv
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
BR112013028128A2 (pt) composição de polímero para dispositivos elétricos
BR112014000445A2 (pt) usos de inibidores de hsp90 marcados
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
DK3395357T3 (da) Sammensætning til kontrolleret ovariestimulering
CO6970598A2 (es) Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BR112013028282A2 (pt) composição de polímero para dispositivos elétricos
DK2925889T3 (da) Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer